Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive Razadyne for Functional Impairments in Schizophrenia
NCT00232349Phase 4Terminated
- Sponsor
- Seattle Institute for Biomedical and Clinical Research
- Start
- Feb 2005
- Primary completion
- Jun 2007
- Countries
- 1
01
Overview
Phase 4, open-label trial of galantamine in schizophrenia and schizoaffective disorder, sponsored by Seattle Institute for Biomedical and Clinical Research. Primary endpoint: Quality of Life Scale at 9 months. Started Feb 2005; status: terminated.
02
Drugs
galantamine
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT00232349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00232349.